Trade BioNTech ^BNTX

BioNTech, Bristol Myers' Pumitamig Shows 36.7% Response Rate In Phase 2 NSCLC Trial

BioNTech (BNTX) Expanded Its Oncology Pipeline, Is It Still 25% Below Fair Value?

Berenberg Bank Sticks to Their Hold Rating for Qiagen (QGEN)

Sterling Capital Management LLC Acquires 88,344 Shares of Gilead Sciences, Inc. $GILD - Stock Observer

7,751 Shares in Gilead Sciences, Inc. $GILD Bought by NBT Bank N.A. - Daily Political

Gilead Sciences, Inc. $GILD Stock Holdings Raised by Royal Fund Management LLC - Zolmax

Gilead Sciences, Inc. $GILD Stock Bought by Royal Fund Management LLC - Markets Daily

Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial

Moderna Tumbles 25% After Apparent Early Leak of Melanoma Vaccine Data; BioNTech Dips, Pfizer Edges Higher

BioNTech Expands Phase 3 Breast Cancer Trial Through Collaboration With Gilead

BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead's TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer | Morningstar

BioNTech (BNTX) Heads To ESMO 2026 With First ROSETTA Lung 107 Data

BNTX: Oncology Execution Matters Most, Cost Cuts Back The Path To Profits

Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline

Trial Miss Might Change The Case For Investing In BioNTech Stock (BNTX)

BioNTech SE Sponsored ADR $BNTX Shares Acquired by Assenagon Asset Management S.A.

BioNTech (NASDAQ:BNTX) Stock Gets Price Target Reduction from Canaccord Genuity Group - Markets Daily

Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put

Moderna Rallies 6% as Money Rotates Into Healthcare; BioNTech and Pfizer Edge Higher

BioNTech (BNTX), What Is Behind The Latest Attention?

BioNTech Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into BioNTech (BNTX) | Morningstar

Canaccord Genuity Group Has Lowered Expectations for BioNTech (NASDAQ:BNTX) Stock Price

BioNTech (NASDAQ:BNTX) Stock Price Target Cut by Canaccord Genuity Group - Daily Political

BioNTech (BNTX) Is Down 7.0% After mRNA Cancer Trial Misses PFS Goal Has The Bull Case Changed?

Critical Analysis: MiMedx Group (NASDAQ:MDXG) vs. BioNTech (NASDAQ:BNTX) - Daily Political

BioNTech's mRNA Cancer Therapy Fails Key Trial Objective in Head and Neck Cancer, ETPharma

What Does BioNTech (BNTX) Trial Miss Mean For Its Oncology Pipeline?

Sivik Global Healthcare LLC Makes New $2.16 Million Investment in BioNTech SE Sponsored ADR $BNTX

BioNTech (NASDAQ:BNTX) Shares Down 5.5% - Here's What Happened

BioNTech mRNA cancer immunotherapy misses first objective in key study

BioNTech Shares Fall 5% as BNT113 Cancer Trial Misses Progression-Free Survival Endpoint

BioNTech stock falls after cancer trial misses key endpoint

BioNTech's BNT113 Misses Progression-Free Survival Endpoint In Phase 3 Head And Neck Cancer Trial

BioNTech Continues AHEAD-MERIT Trial Despite BNT113's PFS Endpoint Miss

Moderna Is Now Worth More Than 3X as Much as BioNTech. Which Biotech Stock Is the Smarter Pick?

BioNTech (NASDAQ:BNTX) Research Coverage Started at Argus - Stock Observer

BioNTech (NASDAQ:BNTX) CEO Sells $2,300,640.00 in Stock - Markets Daily

BioNTech (NASDAQ:BNTX) CEO Sells 27,000 Shares of Company Stock - Markets Daily

BioNTech (NASDAQ: BNTX) CEO sells all direct shares under trading plan - Stock Observer

Moderna stock jumps on planned national cancer vaccine effort

Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up

12,163 BioNTech SE Sponsored ADR $BNTX Shares Sold by Crocodile Capital Partners GmbH - Daily Political

Insider Selling: BioNTech (NASDAQ:BNTX) CEO Sells $7,000,560.00 in Stock - Daily Political

BioNTech (NASDAQ:BNTX) Now Covered by Argus

BioNTech (NASDAQ:BNTX) Stock Picked Up by Analysts at Argus - Zolmax

Is BioNTech (BNTX) Undervalued On Pipeline Promise Despite Revenue Of €2,650.0 Million And Losses?

BioNTech SE Sponsored ADR (NASDAQ:BNTX) Stock Now Rated "Moderate Buy" by Wall Street Analysts - Daily Political

BioNTech (NASDAQ:BNTX) CEO Ugur Sahin Sells 24,000 Shares of Stock

Is BioNTech (NasdaqGS:BNTX) Overvalued As Sales Face A Reset?

BNTX Maintained by Morgan Stanley -- Price Target Lowered to $11

BioNTech (NASDAQ: BNTX) CEO sells 93,000 shares under preplanned deal - Markets Daily

BioNTech (NASDAQ:BNTX) Stock: Insider Ugur Sahin Sells 72,000 Shares

Moderna Is Up 545% in 2026: Take Profits Now, or Keep Buying?

BioNTech (NASDAQ:BNTX) CEO Ugur Sahin Sells 72,000 Shares of Company Stock - Stock Observer

BioNTech SE Sponsored ADR (NASDAQ:BNTX) Stock Has Average Price Target of $126.00 According to Brokerages - Markets Daily

Novavax Soars 22% as Sanofi Carries Nuvaxovid Into Vaccination Season; Moderna Climbs 8%, BioNTech Ticks Up

Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips

BioNTech SE Sponsored ADR (NASDAQ:BNTX) Stock Has Consensus Target Price of $126.00

BioNTech (NASDAQ:BNTX) Stock: Insider Ugur Sahin Sells 17,000 Shares

Moderna Climbs 3% Despite Citigroup's Downgrade to Sell; BioNTech Inches Higher, Pfizer Treads Water

BioNTech (NASDAQ:BNTX) CEO Sells $2,664,630.00 in Stock - Markets Daily

BioNTech (NASDAQ:BNTX) CEO Sells $3,347,980.00 in Stock - Stock Observer

BioNTech CEO sold shares under plan - Stock Observer

BioNTech (NASDAQ:BNTX) CEO Ugur Sahin Sells 32,000 Shares of Stock

BioNTech Closes Manufacturing Sites in Germany and Singapore Amidst Failed Sales, ETPharma

BioNTech (NASDAQ:BNTX) Stock: Insider Ugur Sahin Sells 27,000 Shares

BioNTech (NASDAQ:BNTX) Stock: Insider Ugur Sahin Sells 34,000 Shares

How New Lung Cancer Data And Updated COVID Shot At BioNTech (BNTX) Has Changed Its Investment Story